They can also come in nonstandard doses or alternative dosage forms, such as sublingual (under the tongue) tablets or drops
Efficacy and safety of ITCA 650, a novel drug-device GLP-1 receptor agonist, in Type 2 diabetes uncontrolled with oral antidiabetes drugs: the FREEDOM-1 trial
Educational initiatives and marketing campaigns have effectively communicated the benefits of GLP-1 receptor agonists, leading to a more informed patient population
Researchers are still exploring the link between protein and GLP-1 production, and more human studies are ultimately needed
First-month promotional pricing from altRx may start below $199
Jalleh RJ, Jones KL, Rayner CK, Marathe CS, Wu T, Horowitz M